Investment Rating - The report initiates coverage with a "Buy" rating for the company [8][9]. Core Views - The company is a small molecule innovative drug developer on the verge of launching its first commercial product, Pimicotinib, which has shown significant efficacy and safety in clinical trials [6][8]. - The company is expected to transition from long-term losses to profitability in 2024, driven by licensing agreements and product commercialization [6][23]. - The partnership with Merck for Pimicotinib is a key growth driver, with potential milestone payments and sales royalties expected to enhance revenue [23][24]. Financial Data and Profit Forecast - Revenue projections for 2023 to 2027 are as follows: - 2023: 190 million RMB - 2024: 504 million RMB - 2025E: 612 million RMB - 2026E: 756 million RMB - 2027E: 627 million RMB - Net profit forecasts indicate a turnaround from a loss of 432 million RMB in 2023 to a profit of 28 million RMB in 2024, reaching 151 million RMB by 2026 [7][9]. - The expected PE ratios for 2025 to 2027 are 165X, 69X, and 78X respectively [9]. Product Pipeline and Development - The company has established a comprehensive pipeline with 22 candidate drugs, including 12 in clinical stages, focusing on oncology and expanding into non-oncology areas [30][34]. - Pimicotinib, a CSF-1R inhibitor, is positioned to be the first commercial product, with NDA submissions in China and the US expected in 2025 [34][43]. - Other notable candidates include Epagolatinib for liver cancer and ABSK061 for achondroplasia, showcasing the company's diverse therapeutic focus [8][34]. Market Position and Competitive Landscape - The company is recognized for its differentiated product offerings, with Pimicotinib demonstrating superior efficacy compared to existing treatments in clinical trials [40][41]. - The competitive landscape for CSF-1R inhibitors includes several approved drugs, but Pimicotinib's unique profile positions it favorably for market entry [38][37]. Management Team - The management team possesses extensive experience in drug development and international collaboration, enhancing the company's strategic capabilities [21][22].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][8]. Core Insights - The company is a small molecule innovative drug developer, poised to launch its first commercial product, Pimicotinib, which has shown promising results in clinical trials and is expected to generate significant revenue starting in 2024 [5][7][19]. - The financial projections indicate a substantial increase in revenue and profitability, with expected revenues of RMB 504 million in 2024 and RMB 612 million in 2025, transitioning from losses to profits [6][24]. - The partnership with Merck for Pimicotinib is a key driver for revenue growth, with potential milestone payments and sales royalties expected to enhance financial stability [24][26]. Financial Data and Earnings Forecast - Revenue projections for 2023 to 2027 are as follows: RMB 19 million in 2023, RMB 504 million in 2024, RMB 612 million in 2025, RMB 756 million in 2026, and RMB 627 million in 2027, with significant year-on-year growth rates [6][8]. - The net profit forecast shows a turnaround from a loss of RMB 432 million in 2023 to a profit of RMB 28 million in 2024, reaching RMB 63 million in 2025 and RMB 151 million in 2026 [6][8]. - The company’s price-to-earnings (PE) ratios are projected to be 369.2 in 2024, 164.9 in 2025, and 69.3 in 2026, indicating a strong growth trajectory [6][8]. Product Pipeline and Development - Pimicotinib, a CSF-1R inhibitor, is set to be the company's first commercial product, with NDA submissions in China and the US expected in 2025 [7][46]. - The company has a robust pipeline with 22 candidate drugs, including FGFR inhibitors and PD-L1 small molecules, indicating a diversified approach to drug development [31][53]. - The clinical data for Pimicotinib in treating TGCT shows a 54% overall response rate (ORR) in pivotal trials, outperforming competitors [43][44]. Market Position and Competitive Landscape - The company is positioned to capitalize on unmet medical needs in oncology, particularly with Pimicotinib addressing TGCT and cGvHD, where current treatment options are limited [42][48]. - The collaboration with Merck enhances the company's market presence and commercial capabilities, providing a competitive edge in the pharmaceutical landscape [24][47]. - The report highlights the differentiation of the company's products, suggesting a strong potential for sustained partnerships and revenue generation [10].

Investment Rating - The report maintains a "Buy" rating for Haidilao with a target price of HK$20.40, indicating a potential upside of 53% from the current price of HK$13.36 [3][7]. Core Views - Haidilao's operations showed continued marginal improvement in August, with an increase in table turnover rates compared to July and a slight year-on-year increase [3]. - The company is focusing on enhancing customer experience by launching various themed restaurants and an innovative concept store in Beijing, which aims to improve operational efficiency [3][4]. - Despite a decline in profit and revenue in the first half of 2025, Haidilao maintains a strong cash position with RMB 92 billion in net cash and a high dividend payout ratio of 95% [4][5]. Financial Summary - Revenue projections for 2025-2027 are expected to grow by 3.3%/3.3%/3.1%, reaching RMB 441.5 billion, RMB 455.9 billion, and RMB 470.0 billion respectively [5]. - The net profit forecast for the same period is projected to increase by 2.7%/3.0%/2.9%, amounting to RMB 48.4 billion, RMB 49.8 billion, and RMB 51.2 billion respectively [5]. - The company reported a cash flow from operating activities of RMB 26 billion in the first half of 2025, indicating strong operational cash generation despite lower profits [4]. Operational Insights - Haidilao's strategy has shifted from focusing solely on performance metrics to also considering shareholder returns, with a commitment to reasonable dividends while ensuring future investments [4]. - The company plans to adjust its management approach to better support employees and enhance operational efficiency [4]. - The introduction of the "Red Pomegranate" initiative aims to lower the barriers for entrepreneurship within the company, allowing for collaboration with established external brands [4].

Investment Rating - The report maintains a rating of "Accumulate" for the company [6][10]. Core Views - The company's performance in the first half of 2025 shows stability, with revenue from pharmaceuticals and orthopedics leading the growth. The company continues to prioritize high dividend payouts, reflecting its commitment to shareholder returns [2][10]. Financial Summary - Total revenue for 2023 was 13,243.76 million RMB, with a projected increase to 13,889.42 million RMB in 2025, representing a growth of 6.1%. The net profit for 2023 was 2,001.91 million RMB, with a slight decrease expected to 2,033.02 million RMB in 2025, a decline of 1.6% [4][10]. - The company’s cash dividend ratio increased from 30% prior to 2023 to 40% in 2023, with a further increase to 50% expected by the end of 2024. The mid-year dividend for 2025 is also planned to be maintained at 50% [10]. Revenue Breakdown - The general medical device segment generated revenue of 33.0 billion RMB in the first half of 2025, remaining stable year-on-year. The pharmaceutical packaging segment also maintained revenue at 11.7 billion RMB, with significant growth in automatic injection pens, which saw a sales increase of approximately 200% [10]. - The orthopedics segment reported revenue of 7.3 billion RMB, a slight decrease of 1.6%, but with a substantial increase in segment profit by 74%. The interventional segment's revenue was 9.9 billion RMB, down by 2%, while the blood technology segment grew by 8.1% to 4.5 billion RMB [10]. Earnings Forecast - The report adjusts the earnings per share (EPS) forecast for 2025-2027 to 0.44, 0.50, and 0.56 RMB respectively, down from previous estimates of 0.51, 0.57, and 0.63 RMB [10]. - The target price for 2026 is set at 8.00 RMB, equivalent to 8.76 HKD, based on a target price-to-earnings (PE) ratio of 16X [10]. Market Data - The current stock price is 5.90 HKD, with a market capitalization of 26,967 million HKD and a 52-week price range of 4.15 to 7.22 HKD [7][10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 4.73, representing a potential upside of 37% from the current price of HKD 3.46 [5][7]. Core Insights - The company is expected to enhance its earnings stability through the integration of hydropower assets, which will significantly boost profits. The restructuring will position the company as a comprehensive clean energy flagship platform while focusing on green energy transformation [3][7]. - Despite short-term fluctuations in hydropower water levels and market electricity prices, the diversified generation portfolio is anticipated to lead to improved earnings certainty in the future [7]. Financial Summary - For the fiscal year ending December 31, 2023, the company reported revenue of HKD 44.26 billion, with a projected increase to HKD 54.21 billion in 2024, followed by a slight decline to HKD 50.56 billion in 2025 [4][8]. - The net profit attributable to ordinary shareholders is expected to grow from HKD 2.66 billion in 2023 to HKD 3.36 billion in 2024, reaching HKD 3.85 billion in 2025 [4][8]. - The company’s EBITDA margin is projected to improve from 45.1% in 2024 to 55.6% by 2027, indicating strong operational efficiency [8]. Operational Performance - The company’s total installed capacity reached 53.9 GW as of the first half of 2025, marking an 11.6% year-on-year increase, with clean energy accounting for 81.8% of the total capacity [7]. - The average fuel cost decreased by 14.4% year-on-year, contributing to positive profit growth despite a decline in coal and hydropower sales volumes [7]. Market Position - The company is positioned to benefit from the high valuation and liquidity of the market, particularly through the integration of its core hydropower assets into a dedicated platform [7]. - The company’s dividend payout ratio has remained stable at around 60%, with expectations for further increases in earnings and dividends following the completion of asset integration [7].

Investment Rating - The report assigns an IPO-specific rating of "5.6" to the company, indicating a favorable outlook compared to peers like Geely Automobile [9]. Core Insights - Chery Automobile is recognized as a leading passenger car manufacturer in China, with a strong brand matrix and significant growth potential in various market segments [1][3]. - The company has demonstrated impressive revenue growth, with projected revenues of 926.2 billion, 1,632.1 billion, and 2,699.0 billion yuan from 2022 to 2024, reflecting a compound annual growth rate (CAGR) of 70.7% [1]. - The global passenger car market is expected to grow at a CAGR of 3.5% from 2025 to 2030, with China's market showing a CAGR of 1.9% from 2019 to 2024 [2]. Company Overview - Chery Automobile was established in 1997 and is headquartered in Wuhu, China, with five distinct brands: Chery, Jetour, Exeed, iCAR, and Zhijie, catering to diverse customer needs [1]. - The company has been the top exporter of Chinese passenger cars since 2003, maintaining a strong international presence [1]. Industry Status and Outlook - The global passenger car industry is entering a mature phase, with total sales projected to reach 74.3 million units in 2024 and 100 million units by 2035 [2]. - The Chinese passenger car market is characterized by its size and dynamism, with sales expected to reach 22.7 million units in 2024 [2]. Strengths and Opportunities - Chery's diverse brand portfolio and strong R&D capabilities position it well for future technological advancements and market expansion [3]. - The company is noted for its global capabilities, making it one of the most prominent Chinese passenger car enterprises in international markets [3]. Weaknesses and Risks - The automotive market is highly competitive, with potential cyclical and volatile demand for new energy vehicles [4].

Investment Rating - The report maintains a rating of "Buy" for the company [2][9]. Core Views - The company's performance in the first half of 2025 is under pressure year-on-year, with a slight decline in pre-tax profit after excluding the impact of the Hong Kong international corporate tax reform [9]. - The peak season for refined oil transportation is expected to improve performance in the second half of the year, and the company is likely to enhance its dividend yield options [3][9]. - The company has adjusted its net profit forecasts for 2025-2027 to HKD 22 billion, 24 billion, and 25 billion respectively, considering the impact of income tax [9]. Financial Summary - Total revenue is projected to decrease from HKD 4,034 million in 2024 to HKD 3,606 million in 2027, reflecting a decline of 3% to 6% over the years [5]. - Gross profit is expected to increase slightly from HKD 2,952 million in 2024 to HKD 2,973 million in 2027 [5]. - Net profit (excluding minority interests) is forecasted to grow from HKD 2,106 million in 2024 to HKD 2,435 million in 2027, with a growth rate of 2% to 8% [5]. - The company’s PE ratio is projected to range from 4.84 to 5.48 over the forecast period, while the PB ratio is expected to remain between 0.75 and 0.81 [5]. Market Data - The current stock price is HKD 1.90, with a market capitalization of HKD 11,779 million and a total share count of 6,199 million [6]. - The stock has traded within a range of HKD 1.50 to HKD 2.29 over the past 52 weeks [6]. Dividend Outlook - The company plans to increase its dividend payout ratio from 40% in 2024 to a potential 50%, which could raise the dividend yield from 7.3% to 9% [9].

Investment Rating - The report maintains a "Buy" rating for Tencent Holdings with a target price of HKD 705.0, indicating a potential upside of 6.6% from the current price of HKD 661.50 [3]. Core Insights - Tencent Cloud is focusing on two strategic directions: "intelligentization" and "globalization," with AI-enabled customer solutions and international business growth as key priorities [1][8]. - The company has accelerated the deployment of AI applications across both consumer (C-end) and business (B-end) sectors, showcasing significant growth in user engagement and application usage [7][10]. - Tencent Cloud's international business has seen high double-digit growth over the past year, with the number of overseas customers doubling, positioning it as a preferred choice for over 90% of internet companies and 95% of leading gaming companies going global [1][20]. Financial Summary - For FY23A, Tencent's revenue is reported at RMB 609,015 million, with an adjusted net profit of RMB 157,688 million. Projections for FY24A and FY25E show revenues of RMB 660,257 million and RMB 736,804 million, respectively, with adjusted net profits of RMB 222,703 million and RMB 252,172.5 million [2][27]. - The adjusted earnings per share (EPS) for FY24A is projected at RMB 23.96, increasing to RMB 27.17 in FY25E, reflecting a positive growth trajectory [2][27]. Strategic Developments - Tencent Cloud has launched a comprehensive AI application matrix, with over a hundred applications upgraded to include AI capabilities, enhancing user experience across platforms like WeChat and Tencent Meeting [8][10]. - The company has introduced the "Agent Runtime" solution to support intelligent agents, significantly improving deployment speed and operational efficiency [13][18]. - Tencent Cloud's mixed 3D model has improved modeling accuracy by three times compared to previous versions, facilitating faster production cycles for 3D assets [22][23].

Investment Rating - The report assigns a rating of "Buy" for the company [2]. Core Views - The company is considered a high-quality target with low valuation and high dividends, showing potential for growth due to a favorable supply-demand rebalancing and moderate raw material prices [3]. - The company has a strong customer base and is expected to leverage its mature overseas production capacity to secure more orders in the future [3]. Financial Summary - The projected total revenue for 2024 is HKD 5,061 million, with a year-on-year growth of 20.5%. The net profit attributable to the parent company is expected to be HKD 608 million, reflecting a significant increase of 75.3% [5]. - The company’s PE ratio is projected to be 4.80 in 2024, indicating a low valuation compared to historical averages [5]. Company Overview - The company has over 20 years of experience in elastic fabric production and has established itself as a leader in the lingerie materials market, providing comprehensive procurement solutions for well-known brands [16]. - The company has successfully transitioned to become a significant supplier of sports fabrics, with major clients including ARC'TERYX, NIKE, and adidas [16][27]. Growth Drivers - The company’s revenue has shown a compound annual growth rate (CAGR) of 10.4% from 2011 to 2024, with sports fabric revenue growing at a CAGR of 38.2%, outpacing other categories [44]. - The demand for sports apparel is expected to continue growing, benefiting elastic fabric suppliers as consumer health awareness increases [59]. Future Outlook - The company is well-positioned to benefit from the adjustment of production capacity under new trade dynamics, with a focus on high-quality clients and long-term partnerships [11]. - The company has maintained a stable dividend payout ratio of around 50%, with a dividend yield exceeding 9% for four consecutive years [11].

Investment Rating - The report maintains a "Buy" rating for Baidu Group-SW (9888.HK) with a current price of HKD 131.00 [1] Core Insights - Baidu is not just a search engine; it is expanding its value through a comprehensive AI ecosystem, including AI models, cloud computing, and self-developed chips [4][5] - The company's new AI business revenue surpassed CNY 10 billion for the first time in Q2 2025, marking a 34% year-on-year growth [5] - Baidu's AI cloud revenue grew by 27% year-on-year, with deep collaborations with over 65 central enterprises [5] - The performance of the Kunlun chip P800 shows significant advantages in optimizing inference cost-effectiveness, with a performance improvement of up to 13 times and cost reduction of up to 95% in large-scale inference scenarios [6][7] Summary by Sections Financial Performance - Baidu's revenue forecast for 2025-2027 is adjusted to CNY 130.8 billion, CNY 139.9 billion, and CNY 148.3 billion, reflecting increases of 1.3%, 2.9%, and 3.0% respectively compared to previous estimates [10] - Non-GAAP net profit estimates for the same period are raised to CNY 18.2 billion, CNY 20.5 billion, and CNY 23 billion, with increases of 1.5%, 3.3%, and 3.3% respectively [10] Business Segments - The Robotaxi service, "Luo Bo Kuaipao," saw a 148% year-on-year increase in service usage, reaching over 2.2 million services in Q2 2025, making it the global leader in this sector [7][8] - Baidu's digital human business holds a 9.8% market share in China's AI digital human market, leading the industry [9] - The company has successfully implemented its digital human technology across over 20 industries, enhancing efficiency in finance, education, media, and e-commerce [9] Strategic Collaborations - Baidu signed a strategic cooperation framework agreement with China Merchants Group to collaborate on cutting-edge AI technologies in various sectors, including transportation and finance [4]